Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Assets (2016 - 2025)

Historic Assets for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $519.0 million.

  • ImmunityBio's Assets rose 4235.59% to $519.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $519.0 million, marking a year-over-year increase of 4235.59%. This contributed to the annual value of $382.9 million for FY2024, which is 2408.93% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Assets is $519.0 million, which was up 4235.59% from $402.1 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Assets peaked at $519.0 million during Q3 2025, and registered a low of $209.4 million during Q1 2021.
  • For the 5-year period, ImmunityBio's Assets averaged around $365.8 million, with its median value being $364.6 million (2024).
  • Per our database at Business Quant, ImmunityBio's Assets skyrocketed by 11181.13% in 2021 and then tumbled by 2418.89% in 2025.
  • Quarter analysis of 5 years shows ImmunityBio's Assets stood at $468.9 million in 2021, then decreased by 22.72% to $362.4 million in 2022, then surged by 39.21% to $504.5 million in 2023, then decreased by 24.09% to $382.9 million in 2024, then skyrocketed by 35.53% to $519.0 million in 2025.
  • Its Assets stands at $519.0 million for Q3 2025, versus $402.1 million for Q2 2025 and $303.8 million for Q1 2025.